Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONM100 for Detection of Peritoneal Metastases
NCT04950166Phase 2Completed
- Sponsor
- OncoNano Medicine
- Start
- Nov 2021
- Primary completion
- Dec 2022
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of pegsitacianine in peritoneal carcinomatosis (PC), sponsored by OncoNano Medicine. Primary endpoint: Percentage of Patients That Had at Least One Additional Lesion Detected Under Pegsitacianine Guidance Following CRS That Was Confirmed as Positive for Disease by Pathological Evaluation at 1 day. Started Nov 2021; status: completed.
02
Drugs
pegsitacianine
03
Conditions
peritoneal carcinomatosis (PC)
Beyond the preview
Go deeper on NCT04950166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04950166.